NCT01888484 - Study of Octanorm Subcutaneous IG in Patients With PID | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 9, 2020

Study Completion Date

June 9, 2020

Conditions

Primary Immune Deficiency Disorder

Interventions

BIOLOGICAL

octanorm 16.5%

octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.

Trial Locations (24)

1097

Octapharma Research Site, Budapest

35233

Octapharma Research Site, Birmingham

43617

Octapharma Research Site, Toledo

68046

Octapharma Research Site, Omaha

75034

Octapharma Research Site, Frisco

80112

Octapharma Research Site, Centennial

92123

Octapharma Research Site, San Diego

92697

Octapharma Research Site, Irvine

117198

Octapharma Research Site, Moscow

197101

Octapharma Research Site, Saint Petersburg

620149

Octapharma Research Site, Yekaterinburg

T6G 2V2

Octapharma Research Site, Edmonton

H3H 1P3

Octapharma Research Site, Montreal

656 91

Octapharma Research Site, Brno

775 20

Octapharma Research Site, Olomouc

304 60

Octapharma Research Site, Pilsen

150 06

Octapharma Research Site, Prague

15-274

Octapharma Research Site, Bialystok

30-663

Octapharma Research Site, Krakow

31-024

Octapharma Research Site, Krakow

20-093

Octapharma Research Site, Lublin

Unknown

Octapharma Research Site, Bratislava

Octapharma Research Site, Košice

Octapharma Research Site, Martin